The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Diabetic patients often have ulcers on their lower-limbs that are infected by multiple biofilm-forming genera of bacteria, and the elimination of the biofilm has proven highly successful in resolving such wounds in patients. To that end, antimicrobial peptides have shown potential as a new anti-biofilm approach. The single human cathelicidin peptide LL-37 has been shown to have antimicrobial and anti-biofilm activity against multiple Gram-positive and Gram-negative human pathogens, and have wound-healing effects on the host. The combination of the anti-biofilm effect and wound-healing properties of LL-37 may make it highly effective in resolving polymicrobially infected wounds when topically applied. Such a peptide or its derivatives could be a platform from which to develop new therapeutic strategies to treat biofilm-mediated infections of wounds. This review summarizes known mechanisms that regulate the endogenous levels of LL-37 and discusses the anti-biofilm, antibacterial, and immunological effects of deficient vs. excessive concentrations of LL-37 within the wound environment. Here, we review recent advances in understanding the therapeutic potential of this peptide and other clinically advanced peptides as a potential topical treatment for polymicrobial infected wounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457 · cited 1×
“Antimicrobial peptides are essential components of human innate immunity and contribute to the first line of defense against infection (Zasloff, 2002).”
BackgroundAntimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Brogden, K. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1098 · Cited by 5,829 · cited 2×
“AMPs can inhibit cell wall, nucleic acid, and protein biosynthesis (Brogden, 2005) and are chemotactic for many leukocytes, drawing them to the site of infection or inflammation.”
BackgroundJames, G. A., Swogger, E., Wolcott, R., Pulcini, E. D., Secor, P., Sestrich, J., Costerton, J. W., & Stewart, P. S. (2008) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2007.00321.x · Cited by 1,543 · cited 8×
“These infections are often characterized by polymicrobial infections mediated by biofilm-forming bacteria, including P. aeruginosa (James et al., 2008).”
BackgroundMethodInfluentialEdwards, R., & Harding, K. G. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200404000-00004 · Cited by 1,099 · cited 2×
“LL-37 ANTI-BIOFILM ACTIVITY One of our long term goals is to discover new treatments for polymicrobial infected wounds, which are often biofilm-mediated (Edwards and Harding, 2004).”
BackgroundLL-37, the only human member of the cathelicidin family of antimicrobial peptides
Dürr, U. H. N., Sudheendra, U. S., & Ramamoorthy, A. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.03.030 · Cited by 1,049
APD2: the updated antimicrobial peptide database and its application in peptide design.
Wang, G., Li, X., & Wang, Z. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn823 · Cited by 941 · cited 2×
“(Wang et al., 2009).”
BackgroundSørensen, O. E., Follin, P., Johnsen, A. H., Calafat, J., Tjabringa, G. S., Hiemstra, P. S., & Borregaard, N. (2001) · Blood · doi:10.1182/blood.v97.12.3951 · Cited by 894 · cited 1×
“The LL-37 peptide is produced by proteolytic cleavage (Protease 3) of hCAP-18 that exists at high concentrations in the granules of neutrophils (40 µM or 630 µg 109 cells) (Sørensen et al., 1997, 2001).”
BackgroundHeilborn, J. D., Nilsson, M. F., Sørensen, O., Ståhle-Bäckdahl, M., Kratz, G., Weber, G., & Borregaard, N. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12069.x · Cited by 572
Schierle, C. F., De la Garza, M., Mustoe, T. A., & Galiano, R. D. (2009) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2009.00489.x · Cited by 311
Nagaoka, I., Hirota, S., Niyonsaba, F., Hirata, M., Adachi, Y., Tamura, H., & Heumann, D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3329 · Cited by 258 · cited 1×
“As a counteraction, LL-37 in turn can bind to LPS and prevent its interaction with lipopolysaccharide-binding protein (LBP) and the co-receptor CD14, thus neutralizing the effect of LPS www.frontiersin.org July 2013 | Volume 4 | Article 143 | 5 (Nagaoka et al., 2001; Yoshioka et al., 2008).”
Background
Cited by
Ageitos, J. M., Sánchez-Pérez, A., Calo-Mata, P., & Villa, T. G. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.018 · Cited by 614
Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions
Mohammad, S., & Thiemermann, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594150 · Cited by 585
“Cathelicidin All members of the cathelicidin family of peptides have a conserved amino-terminal cathepsin L inhibitor domain (cathelin) and play an essential role in host defense (99).”
BackgroundMofazzal Jahromi, M. A., Sahandi Zangabad, P., Moosavi Basri, S. M., Sahandi Zangabad, K., Ghamarypour, A., Aref, A. R., Karimi, M., & Hamblin, M. R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.001 · Cited by 551
Advances in Antimicrobial Microneedle Patches for Combating Infections
Jamaledin, R., Yiu, C. K. Y., Zare, E. N., Niu, L., Vecchione, R., Chen, G., Gu, Z., Tay, F. R., & Makvandi, P. (2020) · Advanced Materials · doi:10.1002/adma.202002129 · Cited by 461
Antimicrobial peptides and wound healing: biological and therapeutic considerations
Mangoni, M. L., McDermott, A. M., & Zasloff, M. (2016) · Experimental Dermatology · doi:10.1111/exd.12929 · Cited by 415
The human cathelicidin LL-37 — A pore-forming antibacterial peptide and host-cell modulator
Xhindoli, D., Pacor, S., Benincasa, M., Scocchi, M., Gennaro, R., & Tossi, A. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.11.003 · Cited by 366
Antimicrobial Peptides: An Update on Classifications and Databases
Bin Hafeez, A., Jiang, X., Bergen, P. J., & Zhu, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111691 · Cited by 341
Antimicrobial Defense of the Intestine
Mukherjee, S., & Hooper, L. V. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.028 · Cited by 318
León-Buitimea, A., Garza-Cárdenas, C. R., Garza-Cervantes, J. A., Lerma-Escalera, J. A., & Morones-Ramírez, J. R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01669 · Cited by 274
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Ridyard, K. E., & Overhage, J. (2021) · Antibiotics · doi:10.3390/antibiotics10060650 · Cited by 270
Biofilm-Innate Immune Interface: Contribution to Chronic Wound Formation
Versey, Z., da Cruz Nizer, W. S., Russell, E., Zigic, S., DeZeeuw, K. G., Marek, J. E., Overhage, J., & Cassol, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.648554 · Cited by 253
Antimicrobial peptides: promising compounds against pathogenic microorganisms
Cruz, J., Ortiz, C., Guzmán, F., Fernández-Lafuente, R., & Torres, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140217110155 · Cited by 166
Metadata
- Authors
- Duplantier, A. J., & van Hoek, M. L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 143-143
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2049774740
- Cited by
- 247
- References
- 12
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.